Enzon Pharmaceuticals, Inc. (ENZN)
USD 0.1
(0.0%)
USD 0.1
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.71 Million USD | 0.88% |
| 2022 | 1.69 Million USD | 321.59% |
| 2021 | 403 Thousand USD | -2.18% |
| 2020 | 412 Thousand USD | -2.6% |
| 2019 | 423 Thousand USD | -18.18% |
| 2018 | 517 Thousand USD | 40.49% |
| 2017 | 368 Thousand USD | -60.85% |
| 2016 | 940 Thousand USD | -80.42% |
| 2015 | 4.8 Million USD | -11.7% |
| 2014 | 5.43 Million USD | 191.37% |
| 2013 | 1.86 Million USD | -98.47% |
| 2012 | 122.31 Million USD | -16.24% |
| 2011 | 146.02 Million USD | -6.99% |
| 2010 | 157 Million USD | -43.82% |
| 2009 | 279.46 Million USD | -9.14% |
| 2008 | 307.59 Million USD | -19.85% |
| 2007 | 383.78 Million USD | -16.62% |
| 2006 | 460.27 Million USD | 8.22% |
| 2005 | 425.31 Million USD | -1.85% |
| 2004 | 433.31 Million USD | -0.84% |
| 2003 | 436.98 Million USD | 3.98% |
| 2002 | 420.25 Million USD | 2.33% |
| 2001 | 410.68 Million USD | 4320.7% |
| 2000 | 9.29 Million USD | -0.11% |
| 1999 | 9.3 Million USD | 36.78% |
| 1998 | 6.79 Million USD | -9.33% |
| 1997 | 7.49 Million USD | -17.59% |
| 1996 | 9.1 Million USD | -16.51% |
| 1995 | 10.9 Million USD | 10.1% |
| 1994 | 9.9 Million USD | 7.61% |
| 1993 | 9.2 Million USD | 6.98% |
| 1992 | 8.6 Million USD | 95.45% |
| 1991 | 4.4 Million USD | 10.0% |
| 1990 | 4 Million USD | -18.37% |
| 1989 | 4.9 Million USD | 444.44% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 521 Thousand USD | -69.6% |
| 2024 Q3 | 44.51 Million USD | 10757.07% |
| 2024 Q2 | 410 Thousand USD | -21.31% |
| 2023 Q3 | 44.48 Million USD | 10965.17% |
| 2023 Q2 | 402 Thousand USD | -1.47% |
| 2023 FY | 1.71 Million USD | 0.88% |
| 2023 Q1 | 408 Thousand USD | -75.99% |
| 2023 Q4 | 1.71 Million USD | -96.15% |
| 2022 Q3 | 425 Thousand USD | 12.73% |
| 2022 Q2 | 377 Thousand USD | -8.05% |
| 2022 Q4 | 1.69 Million USD | 299.76% |
| 2022 Q1 | 410 Thousand USD | 1.74% |
| 2022 FY | 1.69 Million USD | 321.59% |
| 2021 Q4 | 403 Thousand USD | 6.9% |
| 2021 Q1 | 461 Thousand USD | 11.89% |
| 2021 FY | 403 Thousand USD | -2.18% |
| 2021 Q2 | 434 Thousand USD | -5.86% |
| 2021 Q3 | 377 Thousand USD | -13.13% |
| 2020 Q4 | 412 Thousand USD | -37.0% |
| 2020 FY | 412 Thousand USD | -2.6% |
| 2020 Q1 | 424 Thousand USD | 0.24% |
| 2020 Q2 | 427 Thousand USD | 0.71% |
| 2020 Q3 | 654 Thousand USD | 53.16% |
| 2019 FY | 423 Thousand USD | -18.18% |
| 2019 Q2 | 455 Thousand USD | -22.22% |
| 2019 Q1 | 585 Thousand USD | 13.15% |
| 2019 Q3 | 5.75 Million USD | 1164.4% |
| 2019 Q4 | 423 Thousand USD | -92.65% |
| 2018 Q4 | 517 Thousand USD | -17.01% |
| 2018 Q1 | 468 Thousand USD | 27.17% |
| 2018 Q2 | 379 Thousand USD | -19.02% |
| 2018 Q3 | 623 Thousand USD | 64.38% |
| 2018 FY | 517 Thousand USD | 40.49% |
| 2017 FY | 368 Thousand USD | -60.85% |
| 2017 Q4 | 368 Thousand USD | -0.81% |
| 2017 Q3 | 371 Thousand USD | -23.82% |
| 2017 Q2 | 487 Thousand USD | 51.24% |
| 2017 Q1 | 322 Thousand USD | -65.74% |
| 2016 Q2 | 150 Thousand USD | -41.41% |
| 2016 Q1 | 256 Thousand USD | -94.67% |
| 2016 Q3 | 163 Thousand USD | 8.67% |
| 2016 FY | 940 Thousand USD | -80.42% |
| 2016 Q4 | 940 Thousand USD | 476.69% |
| 2015 Q2 | 22.82 Million USD | 2053.58% |
| 2015 Q3 | 4.76 Million USD | -79.14% |
| 2015 Q4 | 4.8 Million USD | 0.84% |
| 2015 FY | 4.8 Million USD | -11.7% |
| 2015 Q1 | 1.06 Million USD | -80.5% |
| 2014 FY | 5.43 Million USD | 191.37% |
| 2014 Q3 | 1.1 Million USD | -12.75% |
| 2014 Q2 | 1.26 Million USD | -12.53% |
| 2014 Q1 | 1.44 Million USD | -22.62% |
| 2014 Q4 | 5.43 Million USD | 393.38% |
| 2013 Q2 | 2.6 Million USD | -97.88% |
| 2013 FY | 1.86 Million USD | -98.47% |
| 2013 Q3 | 3.08 Million USD | 18.58% |
| 2013 Q4 | 1.86 Million USD | -39.47% |
| 2013 Q1 | 122.84 Million USD | 0.43% |
| 2012 Q2 | 125.53 Million USD | -10.21% |
| 2012 FY | 122.31 Million USD | -16.24% |
| 2012 Q4 | 122.31 Million USD | -1.96% |
| 2012 Q3 | 124.75 Million USD | -0.62% |
| 2012 Q1 | 139.8 Million USD | -4.26% |
| 2011 Q1 | 153.38 Million USD | -2.3% |
| 2011 FY | 146.02 Million USD | -6.99% |
| 2011 Q2 | 151.24 Million USD | -1.39% |
| 2011 Q4 | 146.02 Million USD | -4.43% |
| 2011 Q3 | 152.79 Million USD | 1.03% |
| 2010 Q2 | 164.59 Million USD | -0.23% |
| 2010 Q4 | 157 Million USD | -4.51% |
| 2010 FY | 157 Million USD | -43.82% |
| 2010 Q1 | 164.97 Million USD | -40.97% |
| 2010 Q3 | 164.41 Million USD | -0.11% |
| 2009 FY | 279.46 Million USD | -9.14% |
| 2009 Q4 | 279.46 Million USD | -1.69% |
| 2009 Q3 | 284.27 Million USD | 1.09% |
| 2009 Q2 | 281.21 Million USD | -0.12% |
| 2009 Q1 | 281.54 Million USD | -8.47% |
| 2008 Q2 | 324.03 Million USD | 1.97% |
| 2008 FY | 307.59 Million USD | -19.85% |
| 2008 Q4 | 307.59 Million USD | -2.4% |
| 2008 Q3 | 315.15 Million USD | -2.74% |
| 2008 Q1 | 317.77 Million USD | -17.2% |
| 2007 Q4 | 383.78 Million USD | -1.56% |
| 2007 Q3 | 389.87 Million USD | -5.42% |
| 2007 FY | 383.78 Million USD | -16.62% |
| 2007 Q1 | 424.29 Million USD | -7.82% |
| 2007 Q2 | 412.2 Million USD | -2.85% |
| 2006 FY | 460.27 Million USD | 8.22% |
| 2006 Q2 | 564.57 Million USD | 35.02% |
| 2006 Q1 | 418.13 Million USD | 0.0% |
| 2006 Q4 | 460.27 Million USD | 7.36% |
| 2006 Q3 | 428.72 Million USD | -24.06% |
| 2005 Q3 | 444.08 Million USD | -0.73% |
| 2005 FY | 425.31 Million USD | -1.85% |
| 2005 Q2 | 447.35 Million USD | 4.05% |
| 2005 Q1 | 429.92 Million USD | -0.8% |
| 2004 Q2 | 433.31 Million USD | 0.03% |
| 2004 Q3 | 428.76 Million USD | -1.05% |
| 2004 FY | 433.31 Million USD | -0.84% |
| 2004 Q4 | 433.4 Million USD | 1.08% |
| 2004 Q1 | 433.18 Million USD | -1.41% |
| 2003 FY | 436.98 Million USD | 3.98% |
| 2003 Q1 | 427.52 Million USD | -4.08% |
| 2003 Q2 | 436.98 Million USD | 2.21% |
| 2003 Q3 | 431.15 Million USD | -1.33% |
| 2003 Q4 | 439.36 Million USD | 1.91% |
| 2002 FY | 420.25 Million USD | 2.33% |
| 2002 Q1 | 414.77 Million USD | -0.87% |
| 2002 Q3 | 414.66 Million USD | -1.33% |
| 2002 Q2 | 420.25 Million USD | 1.32% |
| 2002 Q4 | 445.71 Million USD | 7.49% |
| 2001 Q2 | 410.68 Million USD | 4700.96% |
| 2001 FY | 410.68 Million USD | 4320.7% |
| 2001 Q4 | 418.43 Million USD | 1.16% |
| 2001 Q3 | 413.64 Million USD | 0.72% |
| 2001 Q1 | 8.55 Million USD | 10.57% |
| 2000 Q2 | 9.29 Million USD | -38.03% |
| 2000 FY | 9.29 Million USD | -0.11% |
| 2000 Q4 | 7.73 Million USD | -34.81% |
| 2000 Q3 | 11.86 Million USD | 27.75% |
| 2000 Q1 | 14.99 Million USD | 31.5% |
| 1999 Q4 | 11.4 Million USD | 17.54% |
| 1999 Q1 | 8.19 Million USD | 18.83% |
| 1999 Q2 | 9.3 Million USD | 13.43% |
| 1999 FY | 9.3 Million USD | 36.78% |
| 1999 Q3 | 9.69 Million USD | 4.29% |
| 1998 FY | 6.79 Million USD | -9.33% |
| 1998 Q3 | 6.19 Million USD | -8.82% |
| 1998 Q1 | 6.09 Million USD | -4.69% |
| 1998 Q2 | 6.79 Million USD | 11.48% |
| 1998 Q4 | 6.9 Million USD | 11.31% |
| 1997 Q3 | 7.29 Million USD | -2.67% |
| 1997 Q4 | 6.39 Million USD | -12.33% |
| 1997 Q1 | 7.89 Million USD | -11.24% |
| 1997 FY | 7.49 Million USD | -17.59% |
| 1997 Q2 | 7.49 Million USD | -5.06% |
| 1996 Q4 | 8.89 Million USD | 0.01% |
| 1996 FY | 9.1 Million USD | -16.51% |
| 1996 Q1 | 9.3 Million USD | -4.12% |
| 1996 Q2 | 9.1 Million USD | -2.15% |
| 1996 Q3 | 8.89 Million USD | -2.22% |
| 1995 Q2 | 10.9 Million USD | 3.81% |
| 1995 Q4 | 9.7 Million USD | 4.3% |
| 1995 Q3 | 9.3 Million USD | -14.68% |
| 1995 Q1 | 10.5 Million USD | 19.32% |
| 1995 FY | 10.9 Million USD | 10.1% |
| 1994 Q2 | 9.9 Million USD | 15.12% |
| 1994 Q3 | 9.2 Million USD | -7.07% |
| 1994 FY | 9.9 Million USD | 7.61% |
| 1994 Q4 | 8.8 Million USD | -4.35% |
| 1994 Q1 | 8.6 Million USD | 3.61% |
| 1993 Q1 | 9.1 Million USD | 5.81% |
| 1993 Q4 | 8.3 Million USD | 0.0% |
| 1993 FY | 9.2 Million USD | 6.98% |
| 1993 Q3 | 8.3 Million USD | -9.78% |
| 1993 Q2 | 9.2 Million USD | 1.1% |
| 1992 Q3 | 8.1 Million USD | -5.81% |
| 1992 FY | 8.6 Million USD | 95.45% |
| 1992 Q4 | 8.6 Million USD | 6.17% |
| 1992 Q2 | 8.6 Million USD | 19.44% |
| 1992 Q1 | 7.2 Million USD | 26.32% |
| 1991 FY | 4.4 Million USD | 10.0% |
| 1991 Q4 | 5.7 Million USD | 54.05% |
| 1991 Q1 | 3.4 Million USD | 13.33% |
| 1991 Q3 | 3.7 Million USD | -15.91% |
| 1991 Q2 | 4.4 Million USD | 29.41% |
| 1990 Q4 | 3 Million USD | -9.09% |
| 1990 Q2 | 4 Million USD | 0.0% |
| 1990 Q3 | 3.3 Million USD | -17.5% |
| 1990 FY | 4 Million USD | -18.37% |
| 1989 Q2 | 4.9 Million USD | 0.0% |
| 1989 FY | 4.9 Million USD | 444.44% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -6147.95% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 81.893% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 97.635% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -111.92% |
| Rebus Holdings, Inc. | 5.24 Million USD | 67.303% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 97.096% |
| Qrons Inc. | 1.48 Million USD | -15.133% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -39.78% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 97.712% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -3734.795% |
| Skye Bioscience, Inc. | 14.07 Million USD | 87.82% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 96.785% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 82.112% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -306.577% |
| SQZ Biotechnologies Company | 50.03 Million USD | 96.575% |
| Intellipharmaceutics International Inc. | 12 Million USD | 85.727% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 55.497% |
| Mesoblast Limited | 188.44 Million USD | 99.09% |
| Marizyme, Inc. | 26.67 Million USD | 93.575% |
| Genus plc | 485 Million USD | 99.647% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 70.664% |
| Pharming Group N.V. | 244.07 Million USD | 99.298% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 14.732% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 31.885% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 54.895% |
| ContraFect Corporation | 32.53 Million USD | 94.731% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 13.491% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 55.221% |
| IMV Inc. | 37.93 Million USD | 95.481% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 85.448% |
| MultiCell Technologies, Inc. | 1617.67 USD | -105854.861% |
| ONE Bio Corp. | 27.49 Million USD | 93.766% |
| Accustem Sciences Inc. | 1.07 Million USD | -58.816% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 97.786% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 18.962% |
| Q BioMed Inc. | 8.13 Million USD | 78.925% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 97.933% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 66.693% |
| Biomind Labs Inc. | 1.49 Million USD | -14.372% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 98.556% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 81.044% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 90.687% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -19.537% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -1106.235% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -752.244% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 70.17% |
| GB Sciences, Inc. | 5.41 Million USD | 68.362% |
| Alpha Cognition Inc. | 7.16 Million USD | 76.077% |
| HST Global, Inc. | 593.59 Thousand USD | -188.75% |
| CSL Limited | 18.62 Billion USD | 99.991% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -36.119% |
| Halberd Corporation | 728.71 Thousand USD | -135.207% |
| Enzolytics Inc. | 365.26 Million USD | 99.531% |
| Agentix Corp. | 2.51 Million USD | 31.728% |
| Resverlogix Corp. | 67.39 Million USD | 97.457% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -104.356% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.615% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 93.074% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 85.6% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 53.235% |
| AVAX Technologies, Inc. | 3.99 Million USD | 57.083% |
| Zenith Capital Corp. | 27.56 Thousand USD | -6117.128% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.871% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -618.195% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 54.101% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -151.75% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 36.791% |
| Kadimastem Ltd | 3.5 Million USD | 51.097% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -2460.923% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 96.59% |
| BioStem Technologies, Inc. | 15.9 Million USD | 89.223% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -268.841% |
| LadRx Corporation | 2.2 Million USD | 22.11% |
| Cell Source, Inc. | 15.8 Million USD | 89.157% |
| Regen BioPharma, Inc. | 5.45 Million USD | 68.594% |
| Regen BioPharma, Inc. | 5.45 Million USD | 68.594% |
| NovAccess Global Inc. | 7.86 Million USD | 78.195% |
| Affymax, Inc. | 8.87 Million USD | 80.679% |
| Itoco Inc. | 1.65 Million USD | -3.681% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 16.454% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 71.665% |
| Mobile Lads Corp. | 1.31 Million USD | -30.491% |
| CytoDyn Inc. | 127.89 Million USD | 98.66% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -4000.577% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -9.424% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 84.482% |
| SYBLEU INC | 681.41 Thousand USD | -151.536% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 71.91% |
| International Stem Cell Corporation | 5.27 Million USD | 67.519% |
| Bioxytran, Inc. | 3.24 Million USD | 47.253% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -173.885% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 62.877% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 95.819% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 92.302% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 15.374% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 68.711% |
| Neutra Corp. | 973.52 Thousand USD | -76.06% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 94.093% |
| PureTech Health plc | 125.58 Million USD | 98.635% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 54.38% |
| IXICO plc | 1.9 Million USD | 9.803% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 91.651% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 98.341% |
| CSL Limited | 18.62 Billion USD | 99.991% |
| Cellectis S.A. | 249.36 Million USD | 99.313% |